Related Experiment Video
Updated: May 14, 2026
10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Rationally designed multitarget agents against inflammation and pain
S H Hwang1, A T Wecksler, K Wagner
1Department of Entomology and Comprehensive Cancer Center, University of California, Davis, One Shields Avenue, Davis, CA 95616-8584, USA.
Current Medicinal Chemistry
|February 16, 2013
Summary
Targeting multiple pathways in arachidonic acid (ARA) metabolism offers a promising strategy for treating inflammation and pain. This multitarget approach may enhance efficacy and reduce side effects compared to single-pathway inhibition.
Area of Science:
- Biochemistry
- Pharmacology
- Inflammation Research
Background:
- Arachidonic acid (ARA) metabolism produces bioactive lipids involved in inflammation and pain.
- Non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors target ARA pathways but have adverse effects.
- Inhibiting single ARA pathways can disrupt oxylipin levels, posing risks.
Purpose of the Study:
- To review the crosstalk between cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) pathways in the ARA cascade.
- To summarize current and future multitarget inhibitor strategies for eicosanoid-driven inflammation and pain.
Main Methods:
- Literature review focusing on the interconnectedness of ARA metabolic pathways.
- Analysis of multitarget inhibition strategies for inflammatory conditions.
Main Results:
- The ARA cascade involves complex crosstalk between COX, LOX, and CYP450 pathways.
- Multitarget inhibition is emerging as a viable therapeutic strategy for inflammation and pain.
- Simultaneous inhibition of multiple pathways shows potential for improved efficacy and reduced adverse effects.
Conclusions:
- Understanding the crosstalk within the ARA cascade is crucial for developing effective anti-inflammatory and analgesic therapies.
- Multitarget inhibitors represent a significant advancement in treating eicosanoid-driven inflammation and pain.
- Future research should focus on optimizing multitarget strategies to maximize therapeutic benefits and minimize risks.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:44Nociception
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...